PharmiWeb

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software ...
PR Newswire

Precision BioLogic Leads the Way in Hemophilia Testing

Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...
News Medical

INNOVANCE Antithrombin Assay

INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...
Pharmabiz

Invivoscribe introduces LeukoStrat KMT2A + MRD Assay to advance high-sensitivity leukaemia testing in clinical trials and patient management worldwide

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, announced the addition of the LeukoStrat KMT2A + MRD Assay and Software to its industry-leading oncology ...